Mechanistically, this combination therapy was shown to modulate the lactylation state of ROCK1 and inhibit the ROCK1–DRP1 signaling pathway, thereby preventing mitochondrial fragmentation and enhancing the anti-tumor efficacy of NK cells [90]. Here, ROCK1 is linked to neoplasm.